SLL Clinical Trials in Durham

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - 2020
Terminated
Has Results
  • Chronic Lymphocytic Leukemia
  • +3 more
  • TP-0903
  • TP-0903 and ibrutinib combination therapy
  • Phoenix, Arizona
  • +5 more
2022-04-04
Apr 4, 2022
C
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Recruiting
  • Lymphocytic Leukemia, Chronic
  • SLL
  • Durham, North Carolina
  • +1 more
2021-09-16
Sep 16, 2021